Targeting skeletal muscle AMP-activated protein kinase to treat type 2 diabetes Eric B. TaylorLaurie J. Goodyear Invited Commentary 11 January 2008 Pages: 399 - 401
Management of painful diabetic neuropathy: What is new or in the pipeline for 2007? Dan Ziegler OriginalPaper 11 January 2008 Pages: 409 - 415
Temperature monitoring to assess, predict, and prevent diabetic foot complications Lawrence A. LaveryDavid G. Armstrong OriginalPaper 11 January 2008 Pages: 416 - 419
Neuropathy associated with prediabetes: What is new in 2007? J. Rob SingletonA. Gordon Smith OriginalPaper 11 January 2008 Pages: 420 - 424
The step-by-step program for reducing diabetic foot problems: A model for the developing world Sharad PendseyZulfiqarali G. Abbas OriginalPaper 11 January 2008 Pages: 425 - 428
Pathogenesis of pain in peripheral diabetic neuropathy Nigel A. CalcuttMiroslav Misha Backonja OriginalPaper 11 January 2008 Pages: 429 - 434
Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients Seema BasiJulia B. Lewis OriginalPaper 11 January 2008 Pages: 439 - 442
Diabetes and nephrolithiasis Michel DaudonPaul Jungers OriginalPaper 11 January 2008 Pages: 443 - 448
Obesity, diabetes, and chronic kidney disease Garabed Eknoyan OriginalPaper 11 January 2008 Pages: 449 - 453
Contrast-induced nephropathy: Update with special emphasis on patients with diabetes Richard Solomon OriginalPaper 11 January 2008 Pages: 454 - 458
Examining diabetic nephropathy through the lens of mouse genetics Matthew D. BreyerElena TcheknevaRaymond C. Harris OriginalPaper 11 January 2008 Pages: 459 - 466
Statin therapy in renal disease: Harmful or protective? Peter A. McCulloughLeslie R. Rocher OriginalPaper 11 January 2008 Pages: 467 - 473